~" Hyponatremia frequently complicates the care of neurosurgical patients and requires prompt effective therapy. These patients commonly fulfill the laboratory criteria of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) or cerebral salt wasting; the classification depends on the volume status of the patient. The authors have been dissatisfied with the standard therapy of fluid restriction for the critically ill neurosurgical patient because of 1 ) slow rates of sodium correction; 2) poor applicability in patients requiring multiple intravenous medications and/or nutritional support; and 3) possible dangers of inducing or enhancing cerebral ischemia in patients who already may be fluid-depleted.
H
YPONATREMIA is a common laboratory finding in a variety of medical illnesses, and results from multiple causes. 2"3 Moderate to severe decrements in serum sodium levels may lead to lethargy, confusion, seizures, or coma in otherwise neurologically intact patientsY 2 and experimentally will induce cerebral edema. 2'233~ Hyponatremia may reveal or augment symptoms and signs associated with focal cerebral injury. 27 In individuals with intracranial pathology, symptoms may become evident at less severe degrees of hyponatremia. 36 Therefore, effective early treatment of hyponatremia is an appropriate goal in the care of neurosurgical patients.
Several central nervous system (CNS) disorders lead to hyponatremia associated with excessive renal loss of sodium. 6' 16"29~36~47 ' 50 In the early 1950's, this phenomenon was termed "cerebral salt wasting" and was thought to be caused by a sodium-losing nephropathy induced by CNS pathology. J6. 47 .5o Later, the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) due to endogenous production from bronchogenic carcinoma 48 and exogenous administration of pitressin 35 was described. In these reports, and in others concerning patients with CNS diseases,~4 hyponatremia~ persistent natriuresis, and expansion of the extracellular volume were found. Serum sodium values improved with fluid restriction. Physiological observations have demonstrated that inappropriately high levels of antidiuretic hormone in serum result in water retention and dilutional hyponatremia. Concomitantly, increases in glomerular filtration rates occur with the fluid expansion and lead to the natriuresis seen in SIADH. TM Since extracellular volume measurements are not easily performed in the clinical setting, such measurements are not usually made. Present laboratory criteria necessary for the diagnosis of SIADH include a low serum sodium level and low serum osmolality, an inappropriately high urine sodium level and high urine 48 (3%) * SAH = subarachnoid hemorrhage; AVM = arteriovenous malformation; CNS = central nervous system. t The incidence of hyponatremia treated by urea and saline in some categories or subcategories is shown in parentheses.
osmolality, and the exclusion of prior diuretic therapy and renal, adrenal, cardiac, hepatic, and thyroid dysfunction. Since its description in 1957, SIADH has supplanted cerebral salt wasting as the usual diagnosis of the hyponatremia and natriuresis associated with multiple intracranial disorders. 36 However, some recent clinical 39"44"52 and animal studies 43 have demonstrated decreased extracellular fluid volume related to hypo-R. F. Reeder and R. E. Harbaugh natremia and natriuresis following subarachnoid hemorrhage (SAH). These findings support the original concept that a true syndrome of cerebral salt wasting, and not SIADH, occurs in some hyponatremic neurosurgical patients.
The distinction between cerebral salt wasting and SIADH is not trivial. For the expanded fluid state of patients with true SIADH, fluid restriction is a rational and successful treatment. 7 For volume-contracted patients with cerebral salt wasting, such therapy may not be appropriate. Wijdicks, et al., 51 reported that patients who had suffered SAH and subsequent hyponatremia developed delayed cerebral infarctions at a significantly higher incidence if treated with fluid restriction than with normal maintenance fluid volumes (81% vs 33%). These investigators also found that, following SAH, hyponatremic patients in general suffered a higher incidence of delayed cerebral infarction than those with normal serum sodium values (61% vs 21%). Whether hyponatremia or other factors (such as fluid status or extent of SAH) account for the latter finding is uncertain; however, the study does support the rationale for therapy that is directed at the correction of hyponatremia and that does not lead to dehydration.
We have been dissatisfied with fluid restriction as the treatment for hyponatremia in critically ill neurosurgical patients because of 1) slow rates of sodium correction; 2) poor applicability in patients requiring multiple intravenous medications and/or nutritional support; and 3) possible dangers of inducing or enhancing cerebral ischemia by fluid restriction in patients already suffering fluid depletion, as previously described. In 1980, Decaux, et aL, ~8"2~ first advocated the use of oral urea and increased oral sodium intake for correcting hyponatremia caused by SIADH. Urea induced a mild osmotic diuresis and depressed urinary sodium excretion, while the supplemental salt restored sodium deficits. The same investigators later demonstrated more rapid correction of hyponatremia in neurologically symptomatic SIADH patients using intravenous urea and normal saline. 2~ Since 1981, many patients at our institution have been successfully treated for hypona- tremia from many causes with oral administration of urea and intravenous normal saline therapy. We have exclusively used intravenous urea since 1985, because of the poor palatability of the oral preparation.
Clinical Material and Methods
The pharmacy records at the Dartmouth-Hitchcock Medical Center were utilized to identify all inpatients who received urea therapy between September 1, 1985, and February 28, 1987 . All patient records were reviewed and all neurosurgical patients found were included in the present study. Laboratory data recorded included serum sodium, creatinine, glucose, and blood urea nitrogen (BUN) values at admission, at the time ofhyponatremia diagnosis (index values), and following therapy. Additional data that might prove helpful in determining the cause of hyponatremia (such as a history of diuretic drug use, clinical fluid status, serum osmolality, urine osmolality and sodium levels, tests of thyroid and adrenal function, accurate body weights, and fluid intake/output records) were also recorded, but were not uniformly present in the charts.
Therapy was usually started when the serum sodium level fell to or below 132 mmol/liter. Standard treatment consisted of 40 gm urea dissolved in 100 to 150 ml normal saline given as a slow intravenous drip every 8 hours and an intravenous infusion of normal saline at 60 to 100 ml/hr for 1 to 2 days. Treatment was terminated at 24 hours when serum sodium was 135 mmol/liter or greater, or had increased by 10 retool/ liter or more. Statistical comparisons were made using paired and unpaired two-tailed Student's test.
Results
Intravenous urea and normal saline therapy was used 62 times in 48 patients (3% of all neurosurgical inpatients). Major diagnostic categories, the number of patients in each category, and the incidence of hyponatremia in some categories are presented in Table 1 . Table  2 summarizes laboratory findings for each major subgroup and the total series. For all patients, the mean pretreatment serum sodium level (_ standard deviation) was 130 _ 3 mmol/liter with a range from 119 to 134 mmol/liter. After treatment, there was a significant elevation to 138 _ 4 mmol/liter (range 129 to 148 mmol/liter) (p < 0.001). The mean serum sodium increment was 8 _+ 4 mmol/liter (range 1 to 24 mmol/ liter). Furthermore, the serum sodium values increased by 5 mmol/liter or greater following treatment in 82% of cases. Mild hyponatremia (serum sodium level 130 to 134 mmol/liter in 65% of hyponatremic patients) increased 7 _+ 3 mmol/liter and moderate hyponatremia (serum sodium level 120 to 129 mmol/liter in 34% of hyponatremic patients) increased by 11 _+ 5 mmol]liter (Table 3) . One patient with a serum sodium level of 119 mmol/liter had an increase to 129 mmol/liter after 24 hours of treatment, which corrected to normal the following day without further urea therapy. Only 1 day of treatment was required in 85% of cases. Serum sodium levels on admission averaged in the normal range (137 _+ 5 mmol/liter), indicating the acuteness of hyponatremia in the majority of the patients.
Serum BUN values increased from 15 _+ 8 to 53 _+ 28 mg/dl as a result of therapy, while the serum creatinine level remained unchanged (Table 2 ). There were no complications of therapy. Due to the incompleteness of patient records, it was impossible in most cases to make an accurate determination of the etiology of hyponatremia as either SIADH, cerebral salt wasting, or other causes. However, 24-hour fluid intake and output records (2719 _+ 912 ml intake, 2892 + 1357 ml output) during urea/saline therapy were nearly always present. Because this was a retrospective study, the accuracy of intake and output volumes is not as dependable as it would be in a prospective trial. Nonetheless, these values demonstrate that the serum sodium level was increased without fluid restriction. No reliable statement can be made regarding the degree of diuretic effect induced by the therapy.
Discussion
Treatment of hyponatremia is dictated by the underlying causative disorder in each case. Iatrogenic hyponatremia is frequently induced by various drugs (such as diuretic, barbiturate, hypoglycemic, and antineoplastic agents) or by excessive administration of free water. Non-iatrogenic causes of hyponatremia include endogenous SIADH, hepatic cirrhosis, adrenocortical insufficiency, congestive heart failure, and cachexia. 3 In a prospective analysis of hospitalized general medical/ surgical patients, Anderson, et al., ~ noted that the daily incidence of hyponatremia (_ 130 mmol/liter) was 2.5%. Approximately 50% of these patients met the criteria of SIADH. Incidence rates for clinically defined SIADH have been reported as 5 % of patients suffering head injury, 2s 9% to 18 % of patients suffering SAH, 24'5t and 29% of all patients in a general neurosurgical ward. 29 In the present retrospective series, the incidence of hyponatremia in patients treated by urea (> 90% of all hyponatremic patients on our neurosurgical service) was 3%, but the incidence of SIADH could not be defined because of incomplete laboratory data. Nonetheless, it seems likely that many of these patients, none of whom had clinical signs of fluid overload, suffered some element of neuropathology-induced hyponatremia with inappropriate natriuresis.
The patient's fluid status has been previously mentioned as the distinguishing feature between the true SIADH (increased fluid volume) and the syndrome of cerebral salt wasting (decreased fluid volume). Our desire to avoid the possible danger of fluid restriction in neurosurgical patients who had the latter syndrome led us to administer urea and normal saline, a therapy that potentially could be successful in both syndromes. Other alternative methods for treating SIADH are used when either rapid correction of serum sodium is required or fluid restriction is impossible; these are reviewed by Miyagawa, 4e and include administration of demeclocycline, lithium, furosemide with hypertonic or normal saline, phenytoin, and other osmotic diuretic agents. Demeclocycline and lithium interfere with the generation and function of cyclic 3',5'-adenosine monophosphate, thus inhibiting vasopressin's action on the renal tubule. Unfortunately, both agents are usually slow-acting and can have serious side effects. Phenytoin acts to inhibit vasopressin release and has been advocated for use in patients with disturbed hypothalamicpituitary function, but its general usefulness is not known. The long-loop diuretic agent furosemide can be used for rapid correction of hyponatremia. It induces a marked negative fluid balance in true SIADH, but during therapy urinary sodium loss (which may be large) must be carefully measured and replaced by appropriate volumes of hypertonic saline. The osmotic diuretic urea similarly effects a negative fluid balance, but has the apparent additional advantage of inhibiting natriuresis, thus eliminating the need for frequent urine electrolyte analysis or hypertonic saline infusion. The mechanism of this antinatriuretic effect has not been clearly defined, and whether it is present in both cerebral salt wasting and SIADH is unknown.
Urea, a nonpolar un-ionized metabolite, has long been used as an osmotic diuretic drug and as an agent to reduce intracranial and intraocular pressure.3~ Urea is primarily eliminated by renal excretion. Approxi-mately 40% of filtered urea is reabsorbed in the renal tubule, resulting in an obligatory urinary water loss.l~ As opposed to mannitol, urea enters intracellular spaces throughout the body, 26'33 decreasing the immediate risk of sudden cardiac decompensation due to rapid intravascular volume expansion.l~ However, because urea penetrates into the CNS only about one-tenth as quickly as into muscle, a significant intravascular to CNS urea gradient occurs. 33 Decreases in brain water content and intracranial pressure during urea administration have been measured experimentally and/or clinically. 8-~~ 31,32,34.46.49 Nonetheless, its use as the favored treatment for intracranial hypertension has been supplanted by mannitol, possibly because there is greater potential for "rebound" elevations in intracranial pressure (that is, delayed return of intracranial pressure to higher than pretreatment values) following urea administration, 9'26'34 although the clinical importance of this phenomenon has been debated. ~~ In no instance in our study was urea administered primarily for the treatment of brain edema or intracranial hypertension, but occasionally it was substituted for doses of mannitol in trauma patients when hyponatremia had occurred. No episodes of rebound intracranial hypertension were encountered.
The current use of urea has been rather limited, as more effective diuretic agents have been developed for general medical practice. Oral or intravenous urea administration for the management of migraine attacks ~3 or acute sickle-cell anemia crises 17 has been advocated in the past. More recently, its intravenous use has been reported in the treatment of hyponatremia resulting from not only SIADH, but also cirrhosis 19 or congestive heart failure.~5 These studies support the potential efficacy of urea therapy directed at hyponatremia regardless of etiology, as used in our series.
Extensive experience with urea has demonstrated its safety even at high doses. The most frequent adverse effects are headache, nausea, and vomiting, but these can usually be avoided by keeping the infusion rate of a 30%-or-less solution at no more than 4 ml/minute. 4~ Reported toxicity has been linked to marked degrees of hypertonicity with BUN levels generated from 75 to 300 mg/dl, indicating that its administration in patients with renal impairment should be restricted. 3~ An illustrative case is that of an elderly hyponatremic patient with chronic renal failure (serum creatinine value > 3.0 mg/dl) who, early in our experience with this therapy (prior to the study period), was treated with three 40-gm doses of urea over 24 hours. The patient became confused, short of breath, and severely nauseated. With appropriate supportive care, all symptoms resolved during the following 24 hours. In our studied series, none of the patients had renal failure and no adverse side effects were seen. Hemolysis or increased capillary bleeding, which has been reported to occur following rapid intravenous administration of urea, was not seen in our patients. 4~
A concern with any therapy directed at the rapid correction of hyponatremia is the potentially lethal complication of central pontine myelinolysis. This condition, a demyelinating lesion of the pons, was initially described in alcoholic and/or malnourished patients, 1 a minority of whom are hyponatremic. 12.41 Excessively rapid elevation of the serum sodium level has been implicated as a causative factor in the production of the lesion, but whether changes in sodium values alone can lead to central pontine myelinolysis remains uncertain. 4 Nonetheless, general medical guidelines recommend slow serum sodium correction in asymptomatic patients with chronic hyponatremia and rapid correction of serum sodium by increments of no more than 2 mmol/liter/hr in symptomatic patients with acute hyponatremia. 45 Faster rates of correction and/or total increases in the serum sodium concentration by more than 25 mmol/liter during the initial therapy may combine with other factors to cause irreversible brain injuryJ These recommendations were not exceeded in any of our patients, nor were the pretreatment sodium values the same as those usually seen in patients with this condition.5 The mild and moderate degrees of acute hyponatremia that led to treatment in this series (Table  3 ) reflect both the type of patients and our institutional bias to treat the hyponatremia of neurosurgical patients early in its course. No clinically detectable cases of central pontine myelinolysis occurred in this series. Our experience with oral urea for hyponatremia prior to 1985 was also favorable, but patient complaints of poor palatability and gastrointestinal distress have led to the almost exclusive use of the intravenous route. For some patients, such as outpatients, oral administration is more convenient. Caution must be used when treating patients with liver disease, since colonic urease activity may generate increased serum ammonia levels from orally administered urea, thus initiating or enhancing hepatic encephalopathy. 38 Again, this complication has not been seen in any of our patients.
This study has demonstrated the efficacy of serum sodium correction by intravenous urea/saline therapy in a group of unselected hyponatremic patients. Interestingly, serum sodium increments were greater in patients who had more severe pretreatment hyponatremia (Table 3 ). This finding is not explained by the available data, since no significant difference can be seen in the mean values for fluid intake or output, the number of days of urea therapy, or the pre-or posttreatment BUN levels between the groups. In all of the patients examined at our institution, the serum sodium level was corrected to normal; however, the range of sodium increment was wide (1 to 24 mmol/liter) indicating a variable response to the therapy. The majority of patients (82%) had an increment of 5 mmol/liter or greater. Subsequent to this study period, we have found occasional "nonresponders" (that is, patients with no useful increase in serum sodium levels) despite effective elevations in serum BUN values by urea administration. These patients predominantly, but not exclusively, have suffered from chronic forms of hyponatremia associated with chronic diuretic use. The nature of this problem has been reviewed elsewhere. 28 Our data do not allow the elucidation of urea's mechanism of action (or lack thereof) in either instance.
